Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: Evidence from a meta‐analysis of individual participant data

The incidence of hepatocellular carcinoma (HCC) is increasing in Western countries. Although several clinical factors have been identified, many individuals never develop HCC, suggesting a genetic susceptibility. However, to date, only a few single‐nucleotide polymorphisms have been reproducibly shown to be linked to HCC onset. A variant (rs738409 C>G, encoding for p.I148M) in the PNPLA3 gene is associated with liver damage in chronic liver diseases. Interestingly, several studies have reported that the minor rs738409[G] allele is more represented in HCC cases in chronic hepatitis C (CHC) and alcoholic liver disease (ALD). However, a significant association with HCC related to CHC has not been consistently observed, and the strength of the association between rs738409 and HCC remains unclear. We performed a meta‐analysis of individual participant data including 2,503 European patients with cirrhosis to assess the association between rs738409 and HCC, particularly in ALD and CHC. We found that rs738409 was strongly associated with overall HCC (odds ratio [OR] per G allele, additive model = 1.77; 95% confidence interval [CI]: 1.42‐2.19; P = 2.78 × 10−7). This association was more pronounced in ALD (OR = 2.20; 95% CI: 1.80‐2.67; P = 4.71 × 10−15) than in CHC patients (OR = 1.55; 95% CI: 1.03‐2.34; P = 3.52 × 10−2). After adjustment for age, sex, and body mass index, the variant remained strongly associated with HCC. Conclusion: Overall, these results suggest that rs738409 exerts a marked influence on hepatocarcinogenesis in patients with cirrhosis of European descent and provide a strong argument for performing further mechanistic studies to better understand the role of PNPLA3 in HCC development. (Hepatology 2014;59:2170–2177)

[1]  R. Moreau,et al.  PNPLA3 rs738409, hepatocellular carcinoma occurrence and risk model prediction in patients with cirrhosis. , 2013, Journal of hepatology.

[2]  H. Shiraha,et al.  The impact of patatin-like phospholipase domain-containing protein 3 polymorphism on hepatocellular carcinoma prognosis , 2013, Journal of Gastroenterology.

[3]  J. Borén,et al.  Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro. , 2012, Journal of hepatology.

[4]  J. Borén,et al.  PNPLA3 I148M (rs738409) genetic variant is associated with hepatocellular carcinoma in obese individuals. , 2012, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[5]  J. Zucman‐Rossi,et al.  Single nucleotide polymorphisms and risk of hepatocellular carcinoma in cirrhosis. , 2012, Journal of hepatology.

[6]  L. N. Valenti,et al.  The i148m Pnpla3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls , 2012, BMC Gastroenterology.

[7]  V. Jooste,et al.  712 PNPLA 3 RS738409 GG HOMOZYGOTE STATUS IS ASSOCIATED WITH INCREASED RISK OF HEPATOCELLULAR CARCINOMA IN CIRRHOTIC PATIENTS , 2012 .

[8]  L. N. Valenti,et al.  315 I148M PNPLA3 POLYMORPHISM IS ASSOCIATED WITH CLINICAL FEATURES IN PATIENTS WITH HEPATOCELLULAR CARCINOMA , 2012 .

[9]  D. Franchimont,et al.  PNPLA3 (rs738409 C>G) is a common risk variant associated with hepatocellular carcinoma in alcoholic cirrhosis , 2012, Hepatology.

[10]  F. Lammert,et al.  The PNPLA3 rs738409 148M/M Genotype Is a Risk Factor for Liver Cancer in Alcoholic Cirrhosis but Shows No or Weak Association in Hepatitis C Cirrhosis , 2011, PloS one.

[11]  D. Franchimont,et al.  Common polymorphism in the PNPLA3/adiponutrin gene confers higher risk of cirrhosis and liver damage in alcoholic liver disease. , 2011, Journal of hepatology.

[12]  M. Pirisi,et al.  PNPLA3 rs738409C/G polymorphism in cirrhosis: relationship with the aetiology of liver disease and hepatocellular carcinoma occurrence , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[13]  M. Manns,et al.  Impact of patatin‐like phospholipase‐3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C , 2011, Hepatology.

[14]  S. Sookoian,et al.  Meta‐analysis of the influence of I148M variant of patatin‐like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease , 2011, Hepatology.

[15]  A. Molinaro,et al.  Patatin‐like phospholipase domain containing 3 sequence variant and hepatocellular carcinoma , 2011, Hepatology.

[16]  A. Alisi,et al.  Hepatitis C virus and alcohol: same mitotic targets but different signaling pathways. , 2011, Journal of hepatology.

[17]  P. Ridker,et al.  Genome-Wide Association Analysis of Soluble ICAM-1 Concentration Reveals Novel Associations at the NFKBIK, PNPLA3, RELA, and SH2B3 Loci , 2011, PLoS genetics.

[18]  M. Pirisi,et al.  602 PNPLA3 RS734809 C/G POLYMORPHISM IN LIVER CIRRHOSIS: RELATIONSHIP WITH THE ETIOLOGY OF LIVER DISEASE AND HCC OCCURRENCE , 2011 .

[19]  E. Galmozzi,et al.  Patatin‐Like phospholipase domain‐containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C , 2011, Hepatology.

[20]  Michael Krawczak,et al.  Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in caucasians , 2010, Hepatology.

[21]  P. Haber,et al.  Patatin‐like phospholipase domain containing 3: A case in point linking genetic susceptibility for alcoholic and nonalcoholic liver disease , 2010, Hepatology.

[22]  E. Bugianesi,et al.  Homozygosity for the patatin‐like phospholipase‐3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease , 2010, Hepatology.

[23]  R. Riley,et al.  Meta-analysis of individual participant data: rationale, conduct, and reporting , 2010, BMJ : British Medical Journal.

[24]  David Kershenobich,et al.  Variant in PNPLA3 is associated with alcoholic liver disease , 2010, Nature Genetics.

[25]  F. Marra,et al.  Adipokines in liver diseases , 2009, Hepatology.

[26]  Alexander Pertsemlidis,et al.  Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease , 2008, Nature Genetics.

[27]  Douglas G. Altman,et al.  Statistical Methods for Examining Heterogeneity and Combining Results from Several Studies in Meta‐Analysis , 2008 .

[28]  J. Thompson,et al.  How should we use information about HWE in the meta-analyses of genetic association studies? , 2008, International journal of epidemiology.

[29]  Siobhan M. Dolan,et al.  Assessment of cumulative evidence on genetic associations: interim guidelines. , 2008, International journal of epidemiology.

[30]  H. El‐Serag,et al.  Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. , 2007, Gastroenterology.

[31]  J. Thompson,et al.  The choice of a genetic model in the meta-analysis of molecular association studies. , 2005, International journal of epidemiology.

[32]  Ammarin Thakkinstian,et al.  A method for meta‐analysis of molecular association studies , 2005, Statistics in medicine.

[33]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[34]  John P A Ioannidis,et al.  Commentary: meta-analysis of individual participants' data in genetic epidemiology. , 2002, American journal of epidemiology.

[35]  L Pagliaro,et al.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. , 2001, Journal of hepatology.

[36]  P. Lee,et al.  Publication bias in meta-analysis: its causes and consequences. , 2000, Journal of clinical epidemiology.

[37]  C. Begg,et al.  Operating characteristics of a rank correlation test for publication bias. , 1994, Biometrics.

[38]  M. S. Patel,et al.  An introduction to meta-analysis. , 1989, Health Policy.

[39]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[40]  D. Woodfield Hepatocellular carcinoma. , 1986, The New Zealand medical journal.

[41]  T. Poynard,et al.  The retrieval of randomized clinical trials in liver disease from the medical literature. A comparison of MEDLARS and manual methods. , 1985, Controlled clinical trials.

[42]  D. McFadden Conditional logit analysis of qualitative choice behavior , 1972 .

[43]  H. Akaike Fitting autoregressive models for prediction , 1969 .